KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Net Margin (2016 - 2025)

Emergent BioSolutions (EBS) has 14 years of Net Margin data on record, last reported at 36.72% in Q4 2025.

  • For Q4 2025, Net Margin fell 2064.0% year-over-year to 36.72%; the TTM value through Dec 2025 reached 7.08%, up 2980.0%, while the annual FY2025 figure was 7.08%, 2534.0% up from the prior year.
  • Net Margin reached 36.72% in Q4 2025 per EBS's latest filing, down from 22.15% in the prior quarter.
  • Across five years, Net Margin topped out at 39.07% in Q3 2024 and bottomed at 566.2% in Q2 2024.
  • Average Net Margin over 5 years is 44.49%, with a median of 13.75% recorded in 2021.
  • Peak YoY movement for Net Margin: tumbled -48884bps in 2024, then surged 55768bps in 2025.
  • A 5-year view of Net Margin shows it stood at 24.27% in 2021, then plummeted by -195bps to 22.96% in 2022, then increased by 22bps to 17.9% in 2023, then rose by 10bps to 16.08% in 2024, then plummeted by -128bps to 36.72% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 36.72% in Q4 2025, 22.15% in Q3 2025, and 8.52% in Q2 2025.